Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 20/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | OXTR | P30559 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516823 | 0.90 | AVPR2 (0.61) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL2512459 | 0.89 | AVPR2 (0.72) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL7916913 | 0.88 | AVPR2 (0.66) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL6929159 | 0.86 | AVPR2 (0.73) | AVPR2AVPR1A | |
| SCHEMBL6929168 | 0.84 | AVPR2 (0.74) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL6926726 | 0.84 | AVPR2 (0.74) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL6929383 | 0.83 | AVPR2 (0.70) | AVPR2AVPR1A | |
| SCHEMBL2506775 | 0.82 | AVPR2 (0.64) | AVPR2AVPR1A | |
| SCHEMBL2442901 | 0.82 | AVPR2 (0.62) | AVPR2AVPR1A | |
| SCHEMBL2438261 | 0.81 | AVPR2 (0.49) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373632-B1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER IP GMBH (DE) | 2015-03-04 | — | — | EP | disclosed |
| EP-2373632-B1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER IP GMBH (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8859601-B2 | Substituted benzyl and phenylsulfonyl triazolones, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859601-B2 | Substituted benzyl and phenylsulfonyl triazolones, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859601-B2 | Substituted benzyl and phenylsulfonyl triazolones, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2373632-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010063402-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063402-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | CHUK, BRSK2, IKBKE | AVPR2 4117/4885AVPR1A 4399/4885SLC6A2 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.